Though the sales arms race is over, reps still overcrowd doctors’ waiting rooms today. Although the “more is better” selling technique employed by the largest of pharmas was successful through the late 1990’s and early 2000’s, the tactic quickly met the point of diminishing returns. Doctors, faced with seeing over 15 different reps over the [...]

Medical publications play such an integral to many company’s overall strategies. Publications not only provide substantial value to clinical studies and research data, but also serve as a conduit for communication with scientific and medical communities. This study examines several top companies’ medical publication strategies and tactics to discover and analyze medical publication best practices. [...]

Generic drugs now account for more than 60% of all prescriptions filled in the US, and more than $60 billion worth of drugs face US patent expiration by 2011. Use this report to build a counter-generics strategy that includes long-term, R&D-based lifecycle planning (such as new formulations and next-generation drugs) as well as frontline tactics [...]

In Canada, access to physicians remains one of the top problems of the day for pharmaceutical sales organizations. Though not nearly as overrun as US doctors, top prescribing Canadian physicians can still expect to see as many as 4 to 6 different reps from some larger companies during a given month. Combining access issues with [...]

Fair-market value has been a notoriously difficult concept to master, especially since there are no defined regulations or procedures for calculating thought leader compensation. With state compliance guidelines changing almost on a daily basis, and the potential introduction of federal guidelines on the horizon, thought leader management executives are understandably overwhelmed. This newest report cuts [...]

Pharmaceutical Opinion Leader Management includes detailed strategies for identifying, recruiting, building and maintaining thought leader relationships. The study guides opinion leader management executives with best practices for physicians in all tiers, including local, regional, national and global influencers.
Backed with real-world metrics from more than 40 companies, this study is the perfect guide for : [...]

Make the most of limited resources by benchmarking IVDs’ budgets and staff support for development, marketing, reimbursement and sales. To achieve commercial success, in vitro diagnostic (IVD) companies must earn the approval of several different groups. Regulators, payer organizations, healthcare providers and laboratory technicians ultimately determine the value of a product — and how well [...]

With pipelines diminishing and generics becoming more aggressive, pharmaceutical companies must maximize their brands’ value and time on the market. Strategic and well-orchestrated lifecycle management efforts are crucial to maintaining a brand’s long-term health.
A Guidebook to Pharma Brand Optimization analyzes the inner-workings of lifecycle management strategy, development and implementation processes. This study provides companies with [...]

Explore marketing budgets for 8 brands throughout their first, second and third years of market availability. The brands are marketed in the following markets :
Asia/Japan (two brands) Australia (one brand) Canada (one brand) Mexico (one brand) Philippines (one brand) South Africa (one brand) Sri Lanka (one brand) Each easy-to-navigate brand profile walks you [...]

The commercialization of new drugs continues to challenge companies across the pharmaceutical and biotechnology sectors. This report provides valuable assistance to individuals and teams who seek guidance in the allocation of pre- and post-launch marketing resources. The report breaks down brands’ commercialization spending and headcounts into three time segments and four spending categories.
Time Segments
Phase [...]